Woodline Partners LP Buys 739,713 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

Woodline Partners LP lifted its holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 110.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,410,520 shares of the company's stock after purchasing an additional 739,713 shares during the quarter. Woodline Partners LP owned 2.61% of Fulcrum Therapeutics worth $6,629,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of FULC. MetLife Investment Management LLC grew its stake in shares of Fulcrum Therapeutics by 145.8% in the 4th quarter. MetLife Investment Management LLC now owns 40,107 shares of the company's stock worth $189,000 after buying an additional 23,792 shares in the last quarter. American Century Companies Inc. lifted its holdings in shares of Fulcrum Therapeutics by 5.9% in the 4th quarter. American Century Companies Inc. now owns 120,611 shares of the company's stock valued at $567,000 after acquiring an additional 6,770 shares during the last quarter. Northern Trust Corp grew its position in Fulcrum Therapeutics by 25.1% in the fourth quarter. Northern Trust Corp now owns 710,321 shares of the company's stock worth $3,339,000 after acquiring an additional 142,578 shares in the last quarter. Wells Fargo & Company MN increased its stake in Fulcrum Therapeutics by 34.4% during the fourth quarter. Wells Fargo & Company MN now owns 34,264 shares of the company's stock worth $161,000 after acquiring an additional 8,761 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its stake in Fulcrum Therapeutics by 46.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 52,368 shares of the company's stock worth $247,000 after acquiring an additional 16,656 shares during the last quarter. Institutional investors own 89.83% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. Leerink Partnrs upgraded Fulcrum Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Friday. HC Wainwright restated a "neutral" rating and issued a $4.00 price target on shares of Fulcrum Therapeutics in a research report on Wednesday, February 26th. Cantor Fitzgerald upgraded shares of Fulcrum Therapeutics from a "neutral" rating to an "overweight" rating and set a $10.00 price objective on the stock in a research report on Thursday, May 15th. Finally, Leerink Partners raised shares of Fulcrum Therapeutics from a "market perform" rating to an "outperform" rating and increased their target price for the company from $4.00 to $12.00 in a research note on Friday. One research analyst has rated the stock with a sell rating, three have issued a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $5.83.

Fulcrum Therapeutics Trading Down 1.4%

Shares of NASDAQ FULC traded down $0.09 during midday trading on Tuesday, hitting $6.35. The company's stock had a trading volume of 492,934 shares, compared to its average volume of 970,476. Fulcrum Therapeutics, Inc. has a 12-month low of $2.32 and a 12-month high of $10.13. The firm has a market cap of $342.77 million, a P/E ratio of -20.48 and a beta of 2.29. The business's 50 day moving average is $4.10 and its two-hundred day moving average is $3.93.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported ($0.28) earnings per share for the quarter, topping analysts' consensus estimates of ($0.29) by $0.01. On average, analysts predict that Fulcrum Therapeutics, Inc. will post -0.16 earnings per share for the current fiscal year.

Fulcrum Therapeutics Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.